首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >A rapid, LC-MS/MS assay for quantification of piperacillin and tazobactam in human plasma and pleural fluid; application to a clinical pharmacokinetic study
【24h】

A rapid, LC-MS/MS assay for quantification of piperacillin and tazobactam in human plasma and pleural fluid; application to a clinical pharmacokinetic study

机译:一种快速,LC-MS / MS测定,用于定量哌啶蛋白和人血浆和胸膜液中的哌唑嗪; 应用于临床药代动力学研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Piperacillin, in combination with tazobactam is a common first-line antibiotic used for the treatment of pleural infection, however its pleural pharmacoldnetics and penetration has not previously been reported. The objective of this work was to develop and validate a rapid and sensitive liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay for quantification of piperacillin (PIP) and tazobactam (TAZ). PIP and TAZ were extracted from both human plasma and pleural fluid samples by protein precipitation in methanol containing the internal standards (IS) piperacillin-d(5) (PIP-d(5)) and sulbactam (SUL). Briefly, 5 mu L of sample was mixed with 125 mu L of methanol containing IS, vortexed and centrifuged. Supernatant (50 mu L) was diluted into 500 mu L of mobile phase containing 10 mM of ammonium bicarbonate in LCMS grade water and transferred to the auto sampler tray. Electrospray ionization in positive mode and multiple reaction monitoring (MRM) were used for PIP and PIP-d5 at the transitions m/z 518.2 - 143.2 and m/z 523.2 - 148.2 respectively, and electrospray ionization in negative mode and MRM were used for TAZ and SUL at the transitions m/z 299.1 - 138.1 and m/z 232.4 - 140.1. The chromatographic separation was achieved using an Acquity BEH C-18 column with gradient elution of mobile phase containing 10 mmol/L ammonium bicarbonate in water and methanol. A linear range was observed over the concentration range of 0.25-352 mg/L and 0.25-50.5 mg/L for PIP and TAZ respectively. Complete method validation was performed according to US FDA guidelines for selectivity, specificity, precision and accuracy, LLOQ, matrix effects, recovery and stability, with all results within acceptable limits. This method was successfully applied to two patients with pleural infection and is suitable for further pharmacokinetic studies and therapeutic drug monitoring.
机译:哌啶蛋白,与Tazobactam的组合是用于治疗胸膜感染的常见的一线抗生素,但之前没有报道其胸腔药遗传学和渗透率。这项工作的目的是开发和验证具有串联质谱(LC-MS / MS)测定的快速和敏感的液相色谱,用于定量哌啶(PIP)和Tazobactam(TAZ)。通过含有内标(IS)哌啶-D(5)(PIP-D(5))和苏术酰胺(SUL)的甲醇中的蛋白质沉淀从人血浆和胸膜液中提取蛋白质血浆和胸膜液样品。简而言之,将5μl样品与125μm含有含量的甲醇混合,涡旋和离心。将上清液(50μl)稀释成500μl的流动相,在LCMS等级中含有10mM的碳酸氢铵,并转移到自动取样器托盘中。在过渡M / Z 518.2-143.2和M / Z 523.2 - &gt的过渡时,在阳性模式和多重反应监测(MRM)中用于PIP和PIP-D5中的电喷雾电离。分别为148.2,在过渡M / Z 299.1-&gt的过渡时,使用负模和MRM中的电喷雾电离和MRM。 138.1和m / z 232.4 - & 140.1。使用Acquity BEH C-18柱实现色谱分离,其中在水和甲醇中含有10mmol / L碳酸氢铵的流动相的梯度洗脱。对于PIP和TAZ的0.25-352mg / L和0.25-50.5mg / L的浓度范围观察到线性范围。完整的方法验证是根据美国FDA的选择性,特异性,精度和准确性,LLOQ,矩阵效应,恢复和稳定性的指南进行的,所有结果都在可接受的限度内。该方法已成功应用于两名胸膜感染患者,适用于进一步的药代动力学研究和治疗药物监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号